Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

PRISM PD Study (NLY01-PD-1)


Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of 36 weeks of treatment with NLY01 in early-stage Parkinson’s disease.

The Booth Gardner Parkinson’s Care Center is conducting a study to determine the effectiveness of a study drug relative to placebo in patients with Parkinson’s disease (PD). Study drug or placebo will be given as a weekly subcutaneous injection over 36 weeks.

Who may be eligible to participate?

Subjects 30 to 80 years of age (inclusive) with a confirmed diagnosis of PD. Onset of any parkinsonian motor sign or symptom must be within 5 years before the Screening Visit. Other inclusion/exclusion criteria apply.

What does participation involve?

Participation in this study will involve subjects attending 10 in-person study visits. After instruction, subjects will self-administer the study drug subcutaneously once per week for 36 weeks (36 doses) with safety follow-up visits approximately 4 weeks and 8 weeks after last injection.


Daniel Burdick, MD, Booth Gardner Parkinson’s Care Center

Clinical Trial Categories

  • Parkinson's Disease
EvergreenHealth Research Services at 425-899-5385

Contact Us

Call us at (425) 899-5385 or use our online information request form.

Online Form